时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
However, the direction and magnitude of their associations with psoriasis risk remain uncertain.；A central challenge is distinguishing associations related to medication exposure from those related to the underlying conditions that lead to treatment.；Diabetes, obesity, insulin resistance, dyslipidemia, cardiovascular disease, and chronic kidney disease are associated with psoriasis and may also influence whether glucose-lowering or lipid-lowering therapy is prescribed and which medication is selected.
方法
We also examined whether the findings varied according to medication class, comparator, outcome definition, and study design.；We included longitudinal observational studies according to predefined eligibility criteria to evaluate the association between glucose-lowering or lipid-lowering medication use and either incident psoriasis or first-recorded psoriasis.；For this review, incident psoriasis referred to a newly diagnosed outcome during follow-up in studies that explicitly excluded previously recorded psoriasis before baseline or during a specified pre-index period.；Eligible study designs included cohort, case-control, and nested case-control studies.
核心结论
Most studies used propensity score matching, propensity score weighting, or multivariable regression to control for confounding.；Comparators included other active medications, heterogeneous treatment populations, medication non-users, and groups defined by different exposure durations, intensities, or levels of adherence.；The studies differed substantially in comparator selection, time-zero specification, exposure definition, follow-up rules, and psoriasis outcome definition, and some reports may have drawn on the same or partially overlapping database populations. ‖ 结论：These findings provide background plausibility but do not establish prevention of cutaneous psoriasis or a shared preventive effect across all TZDs.
局限
This systematic review included 18 longitudinal observational reports.；These limitations, together with uncertainty about evidence independence, preclude a stable interpretation of the findings as medication-class effects.；Several Taiwan reports may also have included overlapping populations, limiting their interpretation as independent replications.
对本项目的价值
★☆☆☆☆ 代谢轴既干预敏感性最高，也是老药新用供给最充足的来源。最大样本量约 37,766。
全文来源
PMC JATS 全文（正文 57,876 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Associations of glucose- and lipid-lowering medications with incident or first-recorded psoriasis: a systematic review of real-world observational studies.
- 期刊与标识：Front Pharmacol · PMID 42953016 · DOI 10.3389/fphar.2026.1942307
C 级证据分级：C 级（预印本 / 观点评论，非原始研究）
本文属观点/评论类文献，不是原始研究。其论点依赖于作者对既有证据的梳理与判断，不构成新的实验证据。本站标注 C 级即为此意——阅读时请把它当作「领域内的思考框架」，而非「研究发现」。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。